JP2020524174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524174A5 JP2020524174A5 JP2019571410A JP2019571410A JP2020524174A5 JP 2020524174 A5 JP2020524174 A5 JP 2020524174A5 JP 2019571410 A JP2019571410 A JP 2019571410A JP 2019571410 A JP2019571410 A JP 2019571410A JP 2020524174 A5 JP2020524174 A5 JP 2020524174A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- mutane
- wild
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 108010002350 Interleukin-2 Proteins 0.000 claims 15
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 10
- 238000006467 substitution reaction Methods 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108700004922 F42A Proteins 0.000 claims 2
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102220427331 c.274A>T Human genes 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 102200142011 rs121909050 Human genes 0.000 claims 2
- 102200131576 rs121912452 Human genes 0.000 claims 2
- 102200158049 rs387906619 Human genes 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102220505697 Palmitoyl-protein thioesterase 1_Y45F_mutation Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 102200041867 rs121918148 Human genes 0.000 claims 1
- 102220281620 rs551111938 Human genes 0.000 claims 1
- 229940121497 sintilimab Drugs 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023211159A JP2024028986A (ja) | 2017-06-19 | 2023-12-14 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521957P | 2017-06-19 | 2017-06-19 | |
| US62/521,957 | 2017-06-19 | ||
| US201862679687P | 2018-06-01 | 2018-06-01 | |
| US62/679,687 | 2018-06-01 | ||
| PCT/IB2018/000760 WO2018234862A1 (en) | 2017-06-19 | 2018-06-19 | USES AND METHODS FOR IL-2 SUPERAGONISTS AND AGONISTS AND FUSIONS THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023211159A Division JP2024028986A (ja) | 2017-06-19 | 2023-12-14 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524174A JP2020524174A (ja) | 2020-08-13 |
| JP2020524174A5 true JP2020524174A5 (US20040106767A1-20040603-C00005.png) | 2021-07-29 |
| JP7433051B2 JP7433051B2 (ja) | 2024-02-19 |
Family
ID=64737001
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571410A Active JP7433051B2 (ja) | 2017-06-19 | 2018-06-19 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
| JP2023211159A Pending JP2024028986A (ja) | 2017-06-19 | 2023-12-14 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023211159A Pending JP2024028986A (ja) | 2017-06-19 | 2023-12-14 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
Country Status (7)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN112020510A (zh) * | 2018-03-19 | 2020-12-01 | 茂体外尔公司 | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 |
| US11529402B2 (en) | 2019-01-14 | 2022-12-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| MA55084A (fr) * | 2019-02-28 | 2022-01-05 | Regeneron Pharma | Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau |
| KR20220008811A (ko) * | 2019-03-29 | 2022-01-21 | 엥스띠뛰 퀴리 | 변형된 생물학적 활성을 갖는 인터류킨-2 변이체. |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| CN110256583B (zh) * | 2019-07-11 | 2022-05-20 | 中国科学院生物物理研究所 | 一种il-2突变体与抗体的融合蛋白及其应用 |
| AU2020329933A1 (en) * | 2019-08-15 | 2022-03-24 | Cytimm Therapeutics, Inc. | Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof |
| US20220403026A1 (en) * | 2019-09-18 | 2022-12-22 | The Regents Of The University Of California | Implantable scaffolds and uses thereof for immunotherapy and other uses |
| US20220331415A1 (en) * | 2019-09-18 | 2022-10-20 | The Regents Of The University Of California | Immunoactive microparticles and uses thereof |
| EP4031191A4 (en) * | 2019-09-18 | 2023-10-25 | The Regents of the University of California | PROTEIN-PRODUCING NANOLIPOSOMES AND THEIR USES |
| CN114502736A (zh) * | 2019-10-11 | 2022-05-13 | 蒂尔坦生物制药有限公司 | 编码白介素-2变体(vIL-2)多肽的溶瘤病毒载体 |
| KR102400884B1 (ko) * | 2019-11-15 | 2022-05-23 | 주식회사 제넥신 | 변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도 |
| CA3164731A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| US20230201283A1 (en) * | 2020-01-09 | 2023-06-29 | Pfizer Inc. | Recombinant vaccinia virus |
| JP2023514010A (ja) | 2020-01-10 | 2023-04-05 | ブライト ピーク セラピューティクス エージー | 修飾ｉｌ－２ポリペプチドおよびその使用 |
| AU2021207652B2 (en) | 2020-01-14 | 2023-08-03 | Synthekine, Inc. | Biased IL2 muteins methods and compositions |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US11746137B2 (en) | 2020-03-31 | 2023-09-05 | Hanmi Pharm. Co., Ltd. | Immunostimulating IL-2 analogs |
| WO2021253360A1 (en) * | 2020-06-18 | 2021-12-23 | Proviva Therapeutics (Hong Kong) Limited | Activatable procytokines |
| US20230365642A1 (en) * | 2020-06-24 | 2023-11-16 | Medicenna Therapeutics, Inc. | Bifunctional superkines and uses thereof |
| KR20230023032A (ko) * | 2020-07-14 | 2023-02-16 | 화이자 인코포레이티드 | 재조합 백시니아 바이러스 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022174101A1 (en) * | 2021-02-12 | 2022-08-18 | Synthorx, Inc. | Skin cancer combination therapy with il-2 conjugates and cemiplimab |
| EP4352091A1 (en) * | 2021-05-27 | 2024-04-17 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified chimeric antigen receptor and use thereof |
| EP4384204A1 (en) | 2021-08-13 | 2024-06-19 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| CN115838424A (zh) * | 2021-09-22 | 2023-03-24 | 上海康岱生物医药技术股份有限公司 | 靶向tigit的单克隆抗体 |
| TW202330628A (zh) * | 2021-11-17 | 2023-08-01 | 瑞士商赫孚孟拉羅股份公司 | 蛋白複合體之組成物及其使用方法 |
| WO2024057094A2 (en) * | 2022-09-14 | 2024-03-21 | Medicenna Therapeutics, Inc. | Il-2 superantagonists constructs, methods and uses thereof |
| WO2024133825A1 (en) * | 2022-12-22 | 2024-06-27 | Anaveon AG | Anti-pd-1 antibody antigen-binding domain and immunoconjugate |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816249A (en) | 1981-11-17 | 1989-03-28 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal anti-idiotype antibodies |
| EP0091539B2 (en) | 1982-03-31 | 1996-11-27 | Ajinomoto Co., Inc. | Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5068177A (en) | 1983-12-28 | 1991-11-26 | Scripps Clinic And Research Foundation | Anti-idiotype antibodies induced by synthetic polypeptides |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US4656132A (en) | 1984-03-28 | 1987-04-07 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4572798A (en) | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4931543A (en) | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5227159A (en) | 1989-01-31 | 1993-07-13 | Miller Richard A | Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies |
| NZ234674A (en) | 1989-08-02 | 1992-02-25 | Seragen Inc | Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| WO1994009820A1 (en) | 1992-11-05 | 1994-05-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| US6451308B1 (en) | 1996-04-26 | 2002-09-17 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
| US6645490B2 (en) | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| MXPA02001417A (es) | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| AU7756100A (en) | 1999-10-08 | 2001-04-23 | Curagen Corporation | Interleukin-2 like protein and nucleic acids encoding same |
| PT1230378E (pt) | 1999-11-15 | 2007-09-17 | Onyx Pharma Inc | ''adenovírus oncolítico'' |
| US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| MXPA04005266A (es) | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada. |
| US6894527B1 (en) | 2003-05-12 | 2005-05-17 | Xilinx, Inc. | Evolved circuits for bitstream protection |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| US20060234205A1 (en) | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| CN100361710C (zh) * | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| ES2432141T3 (es) | 2005-01-27 | 2013-11-29 | Novartis Vaccines And Diagnostics, Inc. | Procedimientos para tratar carcinoma de células renales |
| PT1866339E (pt) | 2005-03-25 | 2013-09-03 | Gitr Inc | Moléculas de ligação a gitr e suas utilizações |
| CN101213297B (zh) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| US20100317577A1 (en) | 2005-09-09 | 2010-12-16 | Department Of Health And Human Services | Methods and Compositions for Inhibiting Cell Death or Enhacing Cell Proliferation |
| WO2009046104A1 (en) * | 2007-10-01 | 2009-04-09 | University Of Miami | Aptamer-targeted sirna to prevent attenuation or suppression of t cell function |
| EP2057972A1 (en) | 2007-11-07 | 2009-05-13 | N.V. Organon | Intrauterine deposit |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20100183545A1 (en) | 2008-10-14 | 2010-07-22 | The United States Of America, As Represented By The Secretary, | Targeted cargo protein combination therapy |
| PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
| WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| JP5782385B2 (ja) | 2009-02-17 | 2015-09-24 | ユーシービー ファーマ ソシエテ アノニム | ヒトｏｘ４０に対する特異性を有する抗体分子 |
| CU23734A1 (es) | 2009-11-27 | 2011-11-15 | Centro Inmunologia Molecular | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
| NZ701539A (en) | 2010-03-04 | 2015-04-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2011130434A2 (en) | 2010-04-13 | 2011-10-20 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
| US20120213771A1 (en) | 2010-04-13 | 2012-08-23 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| WO2012054929A2 (en) | 2010-10-22 | 2012-04-26 | Protox Therapeutics Corp. | Use of human serum albumin to decrease antigenicity of therapeutic proteins |
| CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| WO2012119093A1 (en) | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| EP2912466B1 (en) * | 2012-10-26 | 2018-08-29 | Institut Gustave Roussy | Methods for predicting the sensitivity of a subject to immunotherapy |
| CA2901115A1 (en) | 2013-02-15 | 2014-08-21 | The Regents Of The University Of California | Heterodimeric conditionally active chimeric antigen receptor and methods of use thereof |
| WO2015009856A2 (en) | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| EP3049445A4 (en) | 2013-09-24 | 2017-10-25 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
| US10711272B2 (en) * | 2014-01-21 | 2020-07-14 | City Of Hope | CTLA-4 aptamer siRNA species |
| WO2015117229A1 (en) | 2014-02-07 | 2015-08-13 | Mcmaster University | Trifunctional t cell-antigen coupler and methods and uses thereof |
| ES2872848T3 (es) * | 2014-02-21 | 2021-11-02 | Nektar Therapeutics India Pvt Ltd | Agonistas selectivos de IL-2Rbeta en combinación con un anticuerpo anti-CTLA-4 o un anticuerpo anti-PD-1 |
| WO2015164815A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| DK3186283T3 (da) * | 2014-08-29 | 2020-03-02 | Hoffmann La Roche | Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1 |
| AU2015357526B2 (en) * | 2014-12-05 | 2022-03-17 | Eureka Therapeutics, Inc. | Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof |
| MX2017011406A (es) | 2015-03-06 | 2018-06-19 | Sorrento Therapeutics Inc | Terapeuticos de anticuerpo que se unen a tim3. |
| EP3268037B1 (en) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
| CN107406859A (zh) * | 2015-03-17 | 2017-11-28 | 倾斜生物医疗公司 | 编码双特异性抗体的溶瘤腺病毒及与其相关的方法和用途 |
| MX2018002315A (es) | 2015-09-01 | 2018-04-11 | Agenus Inc | Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos. |
| WO2017100541A1 (en) | 2015-12-10 | 2017-06-15 | Gerd Binnig | Methods for treatment and selection of patients responsive to immune mediated cancer therapy |
| MY191649A (en) | 2016-03-04 | 2022-07-05 | Jn Biosciences Llc | Antibodies to tigit |
-
2018
- 2018-06-19 EP EP18820803.7A patent/EP3641814A4/en active Pending
- 2018-06-19 JP JP2019571410A patent/JP7433051B2/ja active Active
- 2018-06-19 CN CN201880053864.6A patent/CN111201035A/zh active Pending
- 2018-06-19 AU AU2018287317A patent/AU2018287317B2/en active Active
- 2018-06-19 CA CA3067909A patent/CA3067909A1/en active Pending
- 2018-06-19 WO PCT/IB2018/000760 patent/WO2018234862A1/en unknown
- 2018-06-19 US US16/012,733 patent/US11542312B2/en active Active
-
2022
- 2022-08-02 US US17/816,823 patent/US20230080403A1/en active Pending
-
2023
- 2023-12-14 JP JP2023211159A patent/JP2024028986A/ja active Pending
